Concentration effect relationship of CYP3A inhibition by ritonavir in humans

[1]  W. Haefeli,et al.  Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity , 2013, European Journal of Clinical Pharmacology.

[2]  C Barbui,et al.  What is the European Medicines Agency? , 2012, Epidemiology and Psychiatric Sciences.

[3]  W. Haefeli,et al.  Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy , 2011, Clinical pharmacology and therapeutics.

[4]  Stephanie Katzenmaier,et al.  Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam , 2010, European Journal of Clinical Pharmacology.

[5]  W. Haefeli,et al.  Effect of Simultaneous Induction and Inhibition of CYP3A by St John's Wort and Ritonavir on CYP3A Activity , 2010, Clinical pharmacology and therapeutics.

[6]  D. Greenblatt,et al.  Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. , 2009, British journal of clinical pharmacology.

[7]  Andrew Hill,et al.  How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials , 2009, AIDS.

[8]  S. West,et al.  Dose–Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure , 2009, Clinical pharmacology and therapeutics.

[9]  D. Greenblatt,et al.  Ritonavir Greatly Impairs CYP3A Activity in HIV Infection With Chronic Viral Hepatitis , 2008, Journal of acquired immune deficiency syndromes.

[10]  Shufeng Zhou,et al.  Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring , 2007, Therapeutic drug monitoring.

[11]  D. Greenblatt,et al.  Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir , 2006, Clinical pharmacology and therapeutics.

[12]  A. Nafziger,et al.  Limited Sampling Models for Oral Midazolam: Midazolam Plasma Concentrations, Not the Ratio of 1‐Hydroxymidazolam to Midazolam Plasma Concentrations, Accurately Predicts AUC as a Biomarker of CYP3A Activity , 2006, Journal of clinical pharmacology.

[13]  M. Concheiro,et al.  A sensitive, rapid and specific determination of midazolam in human plasma and saliva by liquid chromatography/electrospray mass spectrometry. , 2004, Rapid communications in mass spectrometry : RCM.

[14]  D. Greenblatt,et al.  Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[15]  P. Kroboth,et al.  Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping , 2002, Clinical pharmacology and therapeutics.

[16]  D. Greenblatt,et al.  Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole , 2000, European Journal of Clinical Pharmacology.

[17]  D. Greenblatt,et al.  Differential Impairment of Triazolam and Zolpidem Clearance by Ritonavir , 2000, Journal of acquired immune deficiency syndromes.

[18]  J. Gerber,et al.  Neither dapsone hydroxylation nor cortisol 6β-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors , 1998, European Journal of Clinical Pharmacology.

[19]  A. Hsu,et al.  Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. , 1998, Clinical pharmacokinetics.

[20]  J. Leonard,et al.  Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. , 1998, British journal of clinical pharmacology.

[21]  A. D. Rodrigues,et al.  Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.

[22]  F. Guengerich.  Cytochrome p450 and chemical toxicology. , 2008, Chemical research in toxicology.